Abstract
The recently discovered tumor suppressor gene PTEN has been found mutated in many types of advanced tumors. When introduced into tumor cells that lack the wild-type allele of the gene, PTEN was able to suppress the growth of these cells. Here, we have analyzed how PTEN might alter cell cycle-regulatory controls to achieve this growth-inhibitory effect. We found that overexpression of PTEN stimulates the synthesis of three inhibitors of cyclin-dependent kinases, p21WAF1, p27KIP1, and p57,KIP2. This effect is very specific, as the expression of other components of the cell cycle engine, various cyclins and cyclin-dependent kinases, is not affected. For p21WAF1 we show that this induction is due to the p53-independent transcriptional activation of its promoter. In addition, increased expression of PTEN rendered the cells more sensitive to apoptotic cell death. Therefore, our data suggest a two-fold mechanism of growth inhibition by PTEN: one that acts via the increased expression of CKIs such as p21WAF1, and another that augments the cellular propensity for apoptotic cell death.
Similar content being viewed by others
References
Steck PA, Pershouse MA, Jasser SA, Alfred YWK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF, Tavtigian SV: Identification of a candidate tumour suppressor gene, MMAC1, at chromosone 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362, 1997
Myers MP, Tonks NK: PTEN: Sometimes taking it off can be better than putting it on. Am J Hum Genet 61: 1234-1238, 1997
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Michael I, Tycko B, Hibshoosh H, Wigler M H, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275: 1943-1947, 1997
Li D-M Sun H: TEP1, encoded by the candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor β. Cancer Res 57: 2124-2129, 1997
Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R, Tonks NK:P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 94: 9052-9057, 1997
Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM: Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280: 1614-1617, 1998
Tamura M, Gu J, Takino T, Yamada KM: Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: Differential involvement of focal adhesion kinase and p130Cas. Cancer Res 59: 442-449, 1999
Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK: The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A 95: 13513-13518, 1998
Maehama T Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378, 1998
Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, Sellers WR: Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway [In Process Citation]. Proc Natl Acad Sci USA 96: 2110-2115, 1999
Li J, Simpson L, Takahashi M, Miliaresis C, Myers M P, Tonks N, Parsons R: The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene [In Process Citation]. Cancer Res 58: 5667-5672, 1998
Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch DR, Fountain JW, Lugo TG, Huang HJ, Cavenee WK: In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci USA 95: 9418-9423, 1998
Cheney IW, Johnson DE, Vaillancourt M-T, Avanzini J, Morimoto A, Demers GW, Wills KN, Shabram PW, Bolen JB, Tavtigian SV, Bookstein R: Suppression of tumorgenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res 58: 2331-2334, 1998
Furnari FB, Lin H, Huang H-JS, Cavenee WK: Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA 94: 12479-12484, 1997
Li, D.-M. and Sun H: PTEN/MMAC/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 95: 15406-16411, 1998
Morimoto AM, Berson AE, Fujii GH, Teng DH, Tavtigian SV, Bookstein R, Steck PA Bolen JB: Phenotypic analysis of human glioma cells expressing the MMAC1 tumor suppressor phosphatase. Oncogene 18: 1261-1266, 1999
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39, 1998
Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP: Pten is essential for embryonic development and tumour suppression. Nat Genet 19: 348-355, 1998
Morgan DO: Principles of CDK regulation. Nature 374: 131-134, 1997
Graña X, Reddy EP: Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDK's), growth suppressor genes and cylin-dependent kinase inhibitors (CKI's). Oncogene 11: 211-219, 1995
Hunter T, Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994
Harper JW, Elledge SJ: Cdk inhibitors in development and cancer. Curr Opin Genetics Devel 6: 56-64, 1996
Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclindependent kinases. Genes Devel 9: 1149-1163, 1995
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 Tumor suppression. Cell 75: 817-825, 1993
El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994
Sheikh MS, Li X, Chen J, Shao Z, Ordonez JV, Foutana JA: Mechanisms of regulation of WAF1/CIP1 gene expression in human breast carcinoma: Role of p53-dependent and independent signal transduction pathways. Oncogene 9: 3407-3415, 1994
Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB: Progesterone regulates transcription of the p21(WAF1) cyclindependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem 273: 10696-10701, 1998
Alpan RS, Pardee AB: p21WAF1/CIP1/SDI1 is elevated through a p53-independent pathway by mimosine. Cell Growth Diff 7: 893-901, 1996
Liu Y, Martindale JL, Gorospe M, Holbrook NJ: Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res 56: 31-35, 1996
Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge S J: p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 267: 1024-1027, 1995
Prowse DM, Bolgan L, Molnár Á, Dotto GP: Involvement of the SP3 transcription factor in induction of p21Cip1/WAF1 in keratinocyte differentiation. J Biol Chem 272: 1308-1314, 1997
Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2: 72-79, 1996
Waldman T, Lengauer C, Kinzler KW, Vogelstein B: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381: 713-716, 1996
Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993
Banerjee D, Lenz H-J, Schnieders B, Manno DJ, Ju JF, Spears CP, Hochhauser D, Danenberg K, Danenberg P, Bertino JR: Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress. Cell Growth Diff 6: 1405-1413, 1995
Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW, O'Connor PM: p53 mutations are associated with decreased sensitivity of human lymphoma cells to DNA-damaging agents. Cancer Res 54: 5824-5830, 1994
Wu GS, El-Deiry WS: p53 and chemosensitivity. Nat Med 2: 255-256, 1996
Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG: p53 and treatment of bladder cancer. Nature 385: 123-124, 1997
O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace Jr, AJ, Kohn KW: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with the growthinhibitory potency of 123 anticancer drugs. Cancer Res 57: 4285-4300, 1997
Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK: Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54: 649-652, 1994
No D, Yao T-P, Evans RM: Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci USA 93: 3346-3351, 1996
El-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinzler KW, Vogelstein B: Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55: 2910-2919, 1995
Baharians Z, Schönthal AH: Autoregulation of protein phosphatase type 2A expression. J Biol Chem 273: 19019-19024, 1998
Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K: Current Protocols in Molecular Biology. In: V. B. Chanda (ed). John Wiley & Sons, Inc., 1994
Harlow E, Lane D: Antibodies: A Laboratory Manual. Cold Spring Harbor. NY: Cold Spring Harbor Laboratory, 1988
Lassar AB, Davis RL, Wright WE, Kadesch T, Murre C, Voronova A, Baltimore D, Weintraub H: Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell 66: 305-315, 1991
Wu R-C, Schönthal AH: Activation of p53-p21waf1 pathway in response to disruption of cell-matrix interactions. J Biol Chem 272: 29091-29098, 1997
Schönthal AH, Feramisco JR: Inhibition of histone H1 kinase expression, retinoblastoma protein phosphorylation, and cell proliferation by the phosphatase inhibitor okadaic acid. Oncogene 8: 433-441, 1993
Zhang Z, Zheng J, Zhao Y, Li G, Batres Y, Luo MP, Wan M, Ying SY: Overexpression of activin A inhibits growth, induces apoptosis, and supresses tumorgenicity in an androgen-sensitive human prostate cancer cell line LNCaP. Int J Oncol 11: 727-736, 1997
Graham FL, Smiley J, Russell WC, Nairn R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-74, 1977
Moran E: Interaction of adenoviral proteins with pRB and p53. FASEB J 7: 880-885, 1993
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685, 1995
Esposito F, Cuccovillo F, Vanoni M, Cimino F, Anderson CW, Appella E, Russo T: Redox-mediated regulation of p21(waf1/ cip1) expression involves a post-transcriptional mechanism and activation of the mitogen-activated protein kinase pathway. Eur J Biochem 245: 730-737, 1997
Zeng Y-X, El-Deiry WS: Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 12: 1557-1564, 1996
Forman HJ, Cadenas E: Oxidative Stress and Signal Transduction. Chapman & Hall, New York, 1997
Wu R-C, Hohenstein A, Park JM, Qiu X, Mueller S, Cadenas E, Schönthal AH: Role of p53 in aziridinylbenzoquinone-induced p21waf1 expression. Oncogene 17: 357-365, 1998
Qiu X, Forman HJ, Schönthal AH, Cadenas E: Induction of p21 mediated by reactive oxygen species formed during the metabolism of aziridinylbenzoquinones by HCT116 cells. J Biol Chem 271: 31915-31921, 1996
de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, Oliver FJ, Masson M, Dierich A, LeMeur M, Walztinger C, Chambon P, de Murcia G: Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 94: 7303-7307, 1997
Duriez PJ, Shah GM: Cleavage of poly(ADP-ribose) polymerase: A sensitive parameter to study cell death. Biochem Cell Biol 75: 337-349, 1997
Hinds PW, Weinberg RA: Tumor suppressor genes. Curr Opin Genetics Devel 4: 135-141, 1994
Levine A J: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997
Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ, Hamm H, Lindboe CF, Fryns JP, Sijmons RH, Woods DG, Mariman EC, Padberg GW, Kremer H: Germline mutations in the PTEN/ MMAC1 gene in patients with Cowden disease. Hum Mol Genet 6: 1383-1387, 1997
Toker A, Cantley LC: Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 387: 673-676, 1997
Harris CC: p53 Tumor suppressor gene: From the basic research laboratory to the clinic — an abridged historical perspective. Carcinogenesis 17: 1187-1198, 1996
Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway [In Process Citation]. Proc Natl Acad Sci USA 95: 15587-15591, 1998
Hawkins DS, Demers GW, Galloway DA: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898, 1996.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wu, RC., Li, X. & Schönthal, A. Transcriptional activation of p21WAF1by PTEN/MMAC1 tumr suppressor. Mol Cell Biochem 203, 59–71 (2000). https://doi.org/10.1023/A:1007024624967
Issue Date:
DOI: https://doi.org/10.1023/A:1007024624967